Sentence examples for rejection risks from inspiring English sources

Current treatments of bone reconstructions in orthopedic and craniomaxillofacial surgery, including autografts and allografts, are limited by either donor tissue availability, morbidity, and infection of second surgery or immune rejection risks.

The rejection of heart transplants can be minimized through careful donor-patient matching and through the identification and management of rejection risk factors in recipients.

To examine efficacy and safety of dual sirolimus and mycophenolate mofetil systemic immunosuppression as allograft rejection prophylaxis after penetrating keratoplasty in patients at high rejection risk.

However, even in a young blood trial or through a private doctor, with all safety measures in place, there's always a body rejection risk, which can lead to death.

More importantly, patient-specific iPSCs could potentially be used for the same range of clinical applications as ESCs with the added advantage of overcoming the rejection risk after transplantation.

Gene expression profiling in peripheral blood constitutes the basis for an FDA-approved, cost-effective heart transplant rejection risk test.

Meta-analyses have confirmed that rATG induction confers a lower rejection risk compared with no induction [ 95], with similar rates of rejection to alemtuzumab induction [ 96].

Despite the rejection risk rate is controversial in HCV patients the incidence round 40% at 6-months post-LT as reported previously by large cohort studies [ 15].

Novel epigenetic biomarkers will help to establish an "immunological fingerprint" of rejection risk or tolerance during follow-up of transplanted patients.

These variables are coupled with immunological markers of rejection risk: the degree of human leukocyte antigen (HLA) matching, the presence of anti-HLA prior to transplantation [ 88].

In low-risk children, non-randomized trials have suggested that rATG induction can support early (<1 week) steroid discontinuation [ 116] or steroid-free immunosuppression [ 117] with a maintenance regimen of CNI and MMF, with no increase in rejection risk.